Results 321 to 330 of about 131,202 (338)

Investigation of the Pathomechanism of Chronic Cough Using an In Vitro Approach

open access: yes
Clinical &Experimental Allergy, Volume 55, Issue 3, Page 247-249, March 2025.
Umesh Singh, Jonathan A. Bernstein
wiley   +1 more source

SGLT‐2 inhibitors for cardiac amyloidosis: Hype or hope?

open access: yes
European Journal of Clinical Investigation, EarlyView.
Flavio Tangianu   +3 more
wiley   +1 more source

NLRP3 inflammasome inhibitor INF39 attenuated NLRP3 assembly in macrophages

International Immunopharmacology, 2021
INF39 is a nontoxic, irreversible, acrylate-based NLRP3 inhibitor and a further optimization of ethyl 2-((2-chlorophenyl) hydroxyl) methyl) acrylate (INF4E). However, the detail mechanism and the direct target of its anti-inflammatory activity is not clear. Here, we show that INF39 is a specific inhibitor for NLRP3 inflammasome activation.
Yuhua Shi   +4 more
openaire   +3 more sources

Vasculitis and the NLRP3 inflammasome

Current Opinion in Rheumatology, 2023
Purpose of review Vasculitis are a group of heterogeneous conditions characterized by chronic inflammation of blood vessels, leading to tissue destruction and organ failure. Vasculitis is an inflammatory process in which immune effector cells infiltrate blood vessels and surrounding tissues.
Kamel, Hamzaoui, Agnès, Hamzaoui
openaire   +2 more sources

LMP7 inhibits the activation of NLRP3 inflammasome through interaction with NLRP3

Biochemical and Biophysical Research Communications, 2020
The innate immune system recognizes pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) by coding pattern recognition receptors (PRRs). As a well-known inflammasome, NLRP3 plays an essential role in helping the host immune response and driving antiviral processes.
Jing Jin   +4 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy